Firstly, most trials included in the current meta-analysis excluded patients with eGFR less than 30 mL/min/1.73 m2, thus we were not able to assess the effect of SGLT2 inhibitors on patients with stage 4 CKD. This evidence concerns the gene SLC5A2 and chronic kidney disease.